Chembio is Well-Positioned in the Point-of-Care Diagnostic Testing Market
Patented Innovative Dual Path Platform (DPP®) Technology Enables Multiplex Capability With Broad Diagnostic Applications
Broad Product Pipeline in Infectious Disease
Strong Management Team With 200+ Years of Cumulative Experience
Building DPP SARS-CoV-2 Portfolio of Highly Differentiated Tests for Both Antigen and Antibody
Offering High Value Diagnostic Products Targeted At Large Markets
